ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Auto-immunity"

  • Abstract Number: 2453 • 2012 ACR/ARHP Annual Meeting

    The Role of Bob1 in Rheumatoid Arthritis: Potential Implications for Autoimmunity

    Nataliya Yeremenko1, Tineke Cantaert1, Melissa N. van Tok2, Ioana Gofita1, Juan D. Canete3, Paul P. Tak4, Hergen Spits5 and Dominique L. Baeten4, 1Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 3Arthritis Unit. Rheumatology Department, Hospital Clínic, Barcelona, Spain, 4Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 5Tytgat Institute for Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is a prototypic autoimmune disease characterized by a prominent humoral autoimmunity. Of particular relevance is the local production of autoantibodies such…
  • Abstract Number: 2345 • 2012 ACR/ARHP Annual Meeting

    HRES-1/RAB4-Mediated Loss of DRP1 Inhibits Mitophagy, Promotes Accumulation of Mitochondria and Serves As Target for Treatment in SLE

    Tiffany Telarico1, David Fernandez1, Zachary A. Oaks2, Gergely Talaber3, Mark Haas4, Michael P. Madaio5 and Andras Perl6, 1Medicine, SUNY Upstate Medical University, Syracuse, NY, 2SUNY, Syracuse, NY, 3Medicine, SUNY, Syracuse, NY, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5Medical College of Georgia, Augusta, GA, 6Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit accumulation of mitochondria and activation of the mammalian target of rapamycin (mTOR). Although mTOR…
  • Abstract Number: 2326 • 2012 ACR/ARHP Annual Meeting

    Discovery of a Highly Potent, Selective Reversible Covalent  Inhibitor of JAK3 Kinase

    Ronald J. Hill1, Angelina Bisconte1, J. Michael Bradshaw1, Ken Brameld2, Eun Ok Kim1, Xiaoyan Li2, Tim Owens2, Erik Verner2 and David M. Goldstein2, 1Biology, Principia Biopharma, South San Francisco, CA, 2Chemistry, Principia Biopharma

    Background/Purpose: Targeting of the JAK-STAT pathway has been shown to be efficacious for treatment of patients with rheumatoid arthritis through the successful use of pan-JAK…
  • Abstract Number: 1699 • 2012 ACR/ARHP Annual Meeting

    Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry

    Jean Hugues Salmon1, Patrice Cacoub2, Bernard G. Combe3, Jean Sibilia4, Beatrice Pallot Prades5, Olivier Fain6, Alain G. Cantagrel7, Maxime Dougados8, Olivier Meyer9, Philippe Carli10, Edouard Pertuiset11, Isabelle Pane12, Philippe Ravaud13, Xavier Mariette14 and Jacques-Eric Gottenberg15, 1Rheumatology, Reims, France, 2Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 3Rhumatologie, Hopital Lapeyronie, Montpellier, France, 4Rheumatology, CHU Hautepierre, Strasbourg, France, 5Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, 6Internal Medicine, Jean Verdier Hospital, Bondy, France, 7Rheumatology, Place du Docteur Baylac, Toulouse, France, 8Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 9Rheumatology, Hopital Bichat, Paris, France, 10HIA sainte Anne, Toulon, France, 11Rheumatology, Ch Rene Dubos, Pontoise, France, 12Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, 13Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 14Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, 15Rheumatology, Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: Limited data are available regarding the proportion and severity of late onset neutropenia after RTX in large and unselected populations of patients with various…
  • Abstract Number: 1672 • 2012 ACR/ARHP Annual Meeting

    Myosin Skews Effector Immune Cells of Scurfy Mice to Target Muscles in an Adoptive Transfer Model of Myositis

    Nicholas Young1, Rahul Sharma2, Alexandra Friedman3, Benjamin Kaffenberger1 and Wael N. Jarjour4, 1Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, 2Medicine, University of Virginia Health System, Charlottesville, VA, 3Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 4Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH

    Background/Purpose: Myositis is associated with an inflammatory process that results in pronounced muscle weakness and is observed in some regulatory T cell (Treg) deficient mouse…
  • Abstract Number: 1649 • 2012 ACR/ARHP Annual Meeting

    French Cohort Study of 141 Cases of Autoimmune Congenital Heart Block

    Kateri Levesque1, Alice Maltret2, Mohamed Hamidou3, Moez Jallouli4, Jean Loup Pennaforte5, Pauline Orquevaux5, Jean-Charles Piette6, Zahir Amoura4, Francois Barriere7, Jérome Le Bidois2, Laurent Fermont2, Laurence Cohen8, Olivier Meyer9, Olivier Fain10, Arnaud Theulin11, Hugues Lucron12, Francois Sassolas13, Holly Bezanahary14, Gaëlle Guettrot-Imbert15, Pascal Seve16, Elizabeth Diot17, Nathalie Morel1, Christophe Deligny18, Elisabeth Villain2 and Nathalie Costedoat-Chalumeau19, 1Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, 2Cardiology, Groupe Hospitalier Necker - Enfants Malades, Paris, France, 3Internal Medicine Department, Nantes University Hospital, Nantes, France, 4Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, 5Hu Robert Debre, CHU Reims, Reims, France, 6Hospital Pitie, Paris, 7Pediatry, CHU Nantes, Nantes, France, 8Cardiology, Institut Jacques Cartier, 9Rheumatology, Hopital Bichat, Paris, France, 10Internal Medicine, Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, Bondy, France, 11Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Cardiology, CHU Fort-de-France, Fort de France, Martinique, 13Cardiology, CHU Lyon, Lyon, France, 14Internal Medicine, University Hospital of Limoges, Limoges, France, 15Internal Medicine, Hopital Gabriel Montpied, Clermont-Ferrand, France, 16Internal medicine, CHU Lyon, Lyon, France, 17Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, 18Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 19Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France

    Background/Purpose: Cardiac neonatal lupus manifestations mainly include congenital heart block (CHB), endocardial fibroelastosis and dilated cardiomyopathy.  We report the preliminary results of the French registry…
  • Abstract Number: 1072 • 2012 ACR/ARHP Annual Meeting

    Enzymatic Lipid Oxidation Contributes to the Maintenance of Self-Tolerance by Regulating Antigen Clearance and Dendritic Cell Function

    Stefan Uderhardt1, Tobias Rothe1, Elisabeth Zinser2, Olga Oskolkova3, Martin Herrmann4, Alexander Steinkasserer5, Valery Bochkov3, Georg Schett6 and Gerhard Kronke1, 1Internal Medicine 3, University of Erlangen, Erlangen, Germany, 2University of Erlangen, Erlangen, Germany, 3Department of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 4Instiute for Immunology, PhD, Erlangen, Germany, 5Department of Immune Modulation at the Department of Dermatology, University Hospital Erlangen, Erlangen, Germany, 6Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: During inflammation and tissue damage, pathogens as well as dying cells are ingested by different phagocytes such as macrophages and dendritic cells. The uptake…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology